Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Intersectoral MHPSS Emergency Preparedness and Response Plan: In the Context of the Risk of War on Lebanon

 
In response to the escalating situation and war on Lebanon, the Ministry of Public Health (MoPH) has developed and is currently implementing with all stakeholders the:
“National Intersectoral MHPSS Emergency Preparedness and Response Plan: In the Context of the Risk of War on Lebanon "

Developed through a collaborative approach by the National Mental Health Programme (NMHP) with the support of the World Health Organization, UNICEF, and all MHPSS Stakeholders (please refer to the action plan for a full list), this comprehensive plan outlines a proactive approach to anticipating, mitigating, and responding to the psychosocial impacts by focusing on early intervention and support to minimize the adverse effects on individuals, healthcare personnel and communities. It underscores the commitment of the MoPH and the NMHP to safeguard mental health and respond timely and effectively to the psychosocial needs of all populations residing in Lebanon during times of crisis while promoting their resilience.

Key Features of the Plan:
  • Continuity of MHPSS Services: The plan highlights actions to ensure the continued availability and accessibility of MHPSS services across Lebanon.
  • Assurance of Psychotropic Medications: The plan emphasizes ensuring the continuous supply and access to psychotropic medications to all old and new beneficiaries.
  • Communication and Messaging: The plan prioritizes the development and dissemination of key messages and tips on topics related to mental health and well-being that would promote community resilience.
  • Training and Capacity Building: The plan places a strong emphasis on training healthcare professionals and frontline responders in MHPSS principles and practices to provide effective support to service users and providers.
The MoPH is implementing this action plan with all stakeholders, including governmental bodies, local authorities and municipalities, non-governmental organizations, healthcare providers, frontliners, and the international community - Please do reach out if your organization is interested to join in implementing this crucial plan and working together to ensure the mental health and psychosocial support of Lebanon’s residents during times of adversity.

Kindly find a selection of valuable links below:
    1
    ...
ATC Name B/G ↓ Ingredients Dosage Form Price
N05AX08 RISPERIDONE BIOGARAN G Risperidone - 4mg 4mg Tablet, coated, scored 1,105,982 L.L
N05AX08 RISCHOTIC OD 1 G Risperidone - 1mg 1mg Tablet, orally disintegrating 371,157 L.L
N05AX08 RISCHOTIC OD 2 G Risperidone - 2mg 2mg Tablet, orally disintegrating 371,157 L.L
B01AF01 RIBAVAN G Rivaroxaban - 20mg 20mg Tablet, film coated 1,343,843 L.L
N05AX08 RISCHOTIC OD 3 G Risperidone - 3mg 3mg Tablet, orally disintegrating 605,369 L.L
B01AF01 RIXALTA 20 G Rivaroxaban - 20mg 20mg Tablet, film coated 1,164,664 L.L
N05AX08 RISCHOTIC OD 4 G Risperidone - 4mg 4mg Tablet, orally disintegrating 605,369 L.L
B01AF01 RIBAVAN G Rivaroxaban - 10mg 10mg Tablet, film coated 959,888 L.L
B01AF01 RIXALTA 10 G Rivaroxaban - 10mg 10mg Tablet, film coated 671,921 L.L
M05BA07 RISEDRONATE ARROW G Risedronate sodium - 35mg 35mg Tablet, film coated 671,921 L.L
N02CC04 RIZATRIPTAN ARROW G Rizatriptan - 10mg 10mg Tablet 1,182,581 L.L
C09BB07 RAMIPRIL/AMLODIPINE GENERICON G Ramipril - 2.5mg, Amlodipine - 5mg Capsule, hard 1,358,625 L.L
C09BB07 RAMIPRIL/AMLODIPINE GENERICON G Ramipril - 5mg, Amlodipine - 5mg Capsule, hard 1,358,625 L.L
C09BB07 RAMIPRIL/AMLODIPINE GENERICON G Ramipril - 10mg, Amlodipine - 5mg Capsule, hard 1,358,625 L.L
C09BB07 RAMIPRIL/AMLODIPINE GENERICON G Ramipril - 10mg, Amlodipine - 10mg Capsule, hard 1,358,625 L.L
M01AB05 REMETHAN G Diclofenac sodium - 50mg 50mg Tablet 196,201 L.L
M01AB05 ROFENAC D G Diclofenac free acid - 50mg 50mg Tablet, dispersible 408,528 L.L
C03BA11 RAWEL SR G Indapamide - 1.5mg 1.5mg Tablet, prolonged release 362,837 L.L
R05DB13 RAPICOD G Butamirate citrate - 0.15% 0.15% Syrup 296,989 L.L
N05AX15 REAGILA G Cariprazine HCl - 1.5mg 1.5mg Capsule, hard 6,394,003 L.L
N05AX15 REAGILA G Cariprazine HCl - 3mg 3mg Capsule, hard 6,394,003 L.L
A02BC01 RISEK G Omeprazole - 20mg 20mg Capsule, enteric coated 302,365 L.L
N05AX15 REAGILA G Cariprazine HCl - 4.5mg 4.5mg Capsule, hard 6,394,003 L.L
N05AX15 REAGILA G Cariprazine - 6mg 6mg Capsule, hard 6,394,003 L.L
N01AH06 REMIFENTANIL MEDIS G Remifentanil (HCl) - 1mg 1mg Injectable powder 1,101,951 L.L
N01AH06 REMIFENTANIL MEDIS G Remifentanil (HCl) - 5mg 5mg Injectable powder 2,576,146 L.L
P01AB01 RAMAZOL G Metronidazole - 500mg 500mg Tablet 216,359 L.L
A02BC01 RISEK G Omeprazole - 40mg 40mg Capsule, enteric coated 522,755 L.L
G04BE08 RAVANA G Tadalafil - 20mg 20mg Tablet 500,421 L.L
V03AB35 RELANCIUM G Sugammadex - 100mg/ml 100mg/ml Injectable solution 45,660,028 L.L
    1
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025